CN120241745A - 包含羟基酪醇和乳香酸的组合物 - Google Patents

包含羟基酪醇和乳香酸的组合物 Download PDF

Info

Publication number
CN120241745A
CN120241745A CN202510507272.9A CN202510507272A CN120241745A CN 120241745 A CN120241745 A CN 120241745A CN 202510507272 A CN202510507272 A CN 202510507272A CN 120241745 A CN120241745 A CN 120241745A
Authority
CN
China
Prior art keywords
hydroxytyrosol
subject
composition
boswellic acid
akba
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202510507272.9A
Other languages
English (en)
Chinese (zh)
Inventor
泰德·亨德森
大卫·格里芬
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nutramax Laboratories Inc
Original Assignee
Nutramax Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nutramax Laboratories Inc filed Critical Nutramax Laboratories Inc
Publication of CN120241745A publication Critical patent/CN120241745A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/32—Burseraceae (Frankincense family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/32—Burseraceae (Frankincense family)
    • A61K36/324—Boswellia, e.g. frankincense
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
CN202510507272.9A 2016-10-04 2017-04-21 包含羟基酪醇和乳香酸的组合物 Pending CN120241745A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662403807P 2016-10-04 2016-10-04
US62/403,807 2016-10-04
PCT/US2017/028857 WO2018067200A1 (en) 2016-10-04 2017-04-21 Compositions comprising hydroxytyrosol and boswellic acid
CN201780061735.7A CN109789110A (zh) 2016-10-04 2017-04-21 包含羟基酪醇和乳香酸的组合物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201780061735.7A Division CN109789110A (zh) 2016-10-04 2017-04-21 包含羟基酪醇和乳香酸的组合物

Publications (1)

Publication Number Publication Date
CN120241745A true CN120241745A (zh) 2025-07-04

Family

ID=58664857

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202510507272.9A Pending CN120241745A (zh) 2016-10-04 2017-04-21 包含羟基酪醇和乳香酸的组合物
CN201780061735.7A Pending CN109789110A (zh) 2016-10-04 2017-04-21 包含羟基酪醇和乳香酸的组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201780061735.7A Pending CN109789110A (zh) 2016-10-04 2017-04-21 包含羟基酪醇和乳香酸的组合物

Country Status (9)

Country Link
US (5) US10342802B2 (enExample)
EP (2) EP4623994A3 (enExample)
JP (5) JP7079551B2 (enExample)
CN (2) CN120241745A (enExample)
AU (3) AU2017340126B2 (enExample)
CA (1) CA3039233A1 (enExample)
ES (1) ES3040765T3 (enExample)
PL (1) PL3522874T3 (enExample)
WO (1) WO2018067200A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3039233A1 (en) 2016-10-04 2018-04-12 Nutramax Laboratories, Inc. Compositions comprising hydroxytyrosol and boswellic acid
CN115282154A (zh) * 2022-08-15 2022-11-04 武汉科前生物股份有限公司 11-羰基-β-乙酰乳香酸在制备治疗猫传腹药物中的用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6358542B2 (en) 1999-12-20 2002-03-19 Usana, Inc. Antioxidant compositions extracted from olives and olive by-products
US7713569B2 (en) 2000-09-01 2010-05-11 Creagri, Inc. Hydroxytyrosol-rich composition from olive vegetation water and method of use thereof
JP3820218B2 (ja) 2000-09-01 2006-09-13 クレアグリ， インコーポレイテッド 植物水からヒドロキシチロソール富化組成物を得る方法
WO2003068171A2 (en) 2002-02-13 2003-08-21 Creagri, Inc. Method and composition for treatment of inflammation and aids-associated neurological disorders
WO2003077860A2 (en) * 2002-03-13 2003-09-25 Biophysica, Inc. BOSWELLIN COMPOSITIONS ENHANCED WITH 3-β-ACETYL-11-KETO-β-BOSWELLIC ACID (“AKBA”), INDUSTRIAL MANUFACTURE AND THEIR USES
EP1582512A1 (en) 2004-03-31 2005-10-05 Cognis IP Management GmbH Process for obtaining hydroxytyrosol from olive leaves extracts
US7625947B2 (en) 2004-06-18 2009-12-01 Laila Nutraceuticals Analogs of 3-O-acetyl-11-keto-β-boswellic acid
JP2008509224A (ja) * 2004-08-09 2008-03-27 クレアグリ， インコーポレイテッド 炎症状態を治療するためのオリーブ組成物及び方法
CN101516364B (zh) * 2006-07-14 2011-12-28 帝斯曼知识产权资产管理有限公司 组合物及其用于治疗、共治疗或预防炎性病症的用途
WO2008006582A1 (en) * 2006-07-14 2008-01-17 Dsm Ip Assets B.V. Compositions comprising magnolol or honokiol and other active agents for the treatment of inflammatory diseases
JP2008120716A (ja) 2006-11-10 2008-05-29 Eisai Food Chemical Kk 抗炎症剤
WO2010029578A2 (en) 2008-09-15 2010-03-18 Ganga Raju Gokaraju Synergistic anti-inflammatory compositions comprising boswellia serrata extracts
CN102451428A (zh) * 2010-10-14 2012-05-16 中国中医科学院广安门医院 可用于治疗类风湿关节炎的中药组合物
US9144555B2 (en) * 2012-11-30 2015-09-29 Darlene E. McCord Hydroxytyrosol and oleuropein compositions for induction of DNA damage, cell death and LSD1 inhibition
CA3039233A1 (en) 2016-10-04 2018-04-12 Nutramax Laboratories, Inc. Compositions comprising hydroxytyrosol and boswellic acid

Also Published As

Publication number Publication date
EP4623994A2 (en) 2025-10-01
JP2026127783A (ja) 2026-08-06
JP7876938B2 (ja) 2026-06-22
JP2022110125A (ja) 2022-07-28
JP7341596B2 (ja) 2023-09-11
PL3522874T3 (pl) 2025-10-06
EP4623994A3 (en) 2025-11-19
CA3039233A1 (en) 2018-04-12
JP7562225B2 (ja) 2024-10-07
WO2018067200A1 (en) 2018-04-12
JP7079551B2 (ja) 2022-06-02
JP2024166415A (ja) 2024-11-28
AU2017340126B2 (en) 2023-03-02
US10722524B2 (en) 2020-07-28
US20240285648A1 (en) 2024-08-29
JP2019529482A (ja) 2019-10-17
US10342802B2 (en) 2019-07-09
US20200222424A1 (en) 2020-07-16
US11980624B2 (en) 2024-05-14
EP3522874A1 (en) 2019-08-14
US11241444B2 (en) 2022-02-08
ES3040765T3 (en) 2025-11-04
AU2025202875B2 (en) 2026-07-09
US20220110946A1 (en) 2022-04-14
AU2017340126A1 (en) 2019-04-11
AU2023203427B2 (en) 2025-02-06
AU2023203427A1 (en) 2023-06-29
US20180092928A1 (en) 2018-04-05
CN109789110A (zh) 2019-05-21
AU2025202875A1 (en) 2025-05-15
JP2023159387A (ja) 2023-10-31
EP3522874B1 (en) 2025-07-02
US20190231796A1 (en) 2019-08-01

Similar Documents

Publication Publication Date Title
Szymczak et al. Zingiber officinale roscoe: the antiarthritic potential of a popular spice—preclinical and clinical evidence
US20240285648A1 (en) Compositions comprising hydroxytyrosol and boswellic acid
Karmakar et al. Targeting the NLRP3 inflammasome as a novel therapeutic target for osteoarthritis
Li et al. The protective effects and mechanism of Ruyi Zhenbao Pill, a Tibetan medicinal compound, in a rat model of osteoarthritis
Walzer et al. Medical plant extracts for treating knee osteoarthritis: a snapshot of recent clinical trials and their biological background
Nwosu et al. Bioactive lead compounds and molecular targets for the development of antiinflammatory drugs
Shaffique et al. Anti-hyperuricemic potential of Rhododendron tomentosum Harmaja syn. Ledum palustre L. 30c and 1M in potassium oxonate induced rat model
US20090156551A1 (en) Novel composition
Wu The effect of Psidium guajava hydroalcoholic extract on reducing the expression of Resistin and TNF-α genes in articular chondrocytes of patients with knee osteoarthritis
KR20140137557A (ko) 애엽과 전호의 추출 혼합물을 주성분으로 하는 염증성 질환 예방 및 치료용 치료용 천연물 조성물
US20220362172A1 (en) Novel compositions including cannabis and avocado/soybean unsaponifiables and methods of use
Manimekalai et al. Anti-inflammatory and anti-arthritic activity of some indigenous plants: A review
TWI454271B (zh) 一種用於治療骨關節炎的草藥組合物
AU2015372438A1 (en) Formulation and method of use
EP3888669A1 (en) Composition for preventing or treating metabolic bone diseases or menopausal symptoms
NL2039507B1 (en) Composition containing fish bone powder and plant extract for effective improvement in bone joint health
Aniess Effects of feeding some herbs on hyperuricemic rats
Schell A promising natural therapy for equine osteoarthritis
CN115671083A (zh) 用于抑制神经细胞变性的组合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination